356 related articles for article (PubMed ID: 26202204)
1. Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.
Pritchard EM; Dyer MA; Guy RK
Mini Rev Med Chem; 2016; 16(6):430-54. PubMed ID: 26202204
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma.
Pritchard EM; Stewart E; Zhu F; Bradley C; Griffiths L; Yang L; Suryadevara PK; Zhang J; Freeman BB; Guy RK; Dyer MA
Pharm Res; 2014 Nov; 31(11):3060-72. PubMed ID: 24906597
[TBL] [Abstract][Full Text] [Related]
3. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.
Brennan RC; Federico S; Bradley C; Zhang J; Flores-Otero J; Wilson M; Stewart C; Zhu F; Guy K; Dyer MA
Cancer Res; 2011 Jun; 71(12):4205-13. PubMed ID: 21515735
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.
Elison JR; Cobrinik D; Claros N; Abramson DH; Lee TC
Arch Ophthalmol; 2006 Sep; 124(9):1269-75. PubMed ID: 16966622
[TBL] [Abstract][Full Text] [Related]
5. Targeting MDM2 and MDMX in retinoblastoma.
Laurie NA; Shih CS; Dyer MA
Curr Cancer Drug Targets; 2007 Nov; 7(7):689-95. PubMed ID: 18045074
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule MDM2-p53 inhibitors: recent advances.
Zhang B; Golding BT; Hardcastle IR
Future Med Chem; 2015; 7(5):631-45. PubMed ID: 25921402
[TBL] [Abstract][Full Text] [Related]
7. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Platelet-Derived Growth Factor-beta Stimulatory Circuitry to Control Retinoblastoma Seeds.
Goldsmith ZK; Coppess W; Irvine AS; Yuan K; Barsh SR; Ritter MK; McEwen MW; Flores-Otero J; Garcia-Vargas A; Martinez-Ferrer M; Brennan RC; Morales-Tirado VM; Wilson MW
Invest Ophthalmol Vis Sci; 2018 Sep; 59(11):4486-4495. PubMed ID: 30193324
[TBL] [Abstract][Full Text] [Related]
9. A novel retinoblastoma therapy from genomic and epigenetic analyses.
Zhang J; Benavente CA; McEvoy J; Flores-Otero J; Ding L; Chen X; Ulyanov A; Wu G; Wilson M; Wang J; Brennan R; Rusch M; Manning AL; Ma J; Easton J; Shurtleff S; Mullighan C; Pounds S; Mukatira S; Gupta P; Neale G; Zhao D; Lu C; Fulton RS; Fulton LL; Hong X; Dooling DJ; Ochoa K; Naeve C; Dyson NJ; Mardis ER; Bahrami A; Ellison D; Wilson RK; Downing JR; Dyer MA
Nature; 2012 Jan; 481(7381):329-34. PubMed ID: 22237022
[TBL] [Abstract][Full Text] [Related]
10. Monitoring Ligand-Induced Protein Ordering in Drug Discovery.
Grace CR; Ban D; Min J; Mayasundari A; Min L; Finch KE; Griffiths L; Bharatham N; Bashford D; Kiplin Guy R; Dyer MA; Kriwacki RW
J Mol Biol; 2016 Mar; 428(6):1290-1303. PubMed ID: 26812210
[TBL] [Abstract][Full Text] [Related]
11. Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
Laurie NA; Gray JK; Zhang J; Leggas M; Relling M; Egorin M; Stewart C; Dyer MA
Clin Cancer Res; 2005 Oct; 11(20):7569-78. PubMed ID: 16243833
[TBL] [Abstract][Full Text] [Related]
12. KIF14 as an oncogene in retinoblastoma: a target for novel therapeutics?
Basavarajappa HD; Corson TW
Future Med Chem; 2012 Nov; 4(17):2149-52. PubMed ID: 23190103
[No Abstract] [Full Text] [Related]
13. Triggering p53 activation is essential in ziyuglycoside I-induced human retinoblastoma WERI-Rb-1 cell apoptosis.
Zhu X; Wang K; Yao Y; Zhang K; Zhou F; Zhu L
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 28960612
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the p53 pathway in peripheral blood of retinoblastoma patients; potential biomarkers.
Martínez-Sánchez M; Moctezuma-Dávila M; Hernandez-Monge J; Rangel-Charqueño M; Olivares-Illana V
PLoS One; 2020; 15(6):e0234337. PubMed ID: 32502182
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation.
Kawano T; Akiyama M; Agawa-Ohta M; Mikami-Terao Y; Iwase S; Yanagisawa T; Ida H; Agata N; Yamada H
Int J Oncol; 2010 Oct; 37(4):787-95. PubMed ID: 20811699
[TBL] [Abstract][Full Text] [Related]
16. SYK is a target of lymphocyte-derived microparticles in the induction of apoptosis of human retinoblastoma cells.
Qiu Q; Yang C; Xiong W; Tahiri H; Payeur M; Superstein R; Carret AS; Hamel P; Ellezam B; Martin B; Vezina M; Sapieha P; Liu G; Hardy P
Apoptosis; 2015 Dec; 20(12):1613-22. PubMed ID: 26404525
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of the p53 pathway in retinoblastoma.
Laurie NA; Donovan SL; Shih CS; Zhang J; Mills N; Fuller C; Teunisse A; Lam S; Ramos Y; Mohan A; Johnson D; Wilson M; Rodriguez-Galindo C; Quarto M; Francoz S; Mendrysa SM; Guy RK; Marine JC; Jochemsen AG; Dyer MA
Nature; 2006 Nov; 444(7115):61-6. PubMed ID: 17080083
[TBL] [Abstract][Full Text] [Related]
18. Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
He S; Dong G; Wu S; Fang K; Miao Z; Wang W; Sheng C
J Med Chem; 2018 Aug; 61(16):7245-7260. PubMed ID: 30045621
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
Shangary S; Wang S
Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305
[TBL] [Abstract][Full Text] [Related]
20. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Riccaboni M; Bianchi I; Petrillo P
Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
